334 related articles for article (PubMed ID: 33389563)
1. Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.
Lee D; Riestenberg RA; Haskell-Mendoza A; Bloch O
J Neurooncol; 2021 Mar; 152(1):89-98. PubMed ID: 33389563
[TBL] [Abstract][Full Text] [Related]
2. Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review.
Grogan D; Bray DP; Cosgrove M; Boucher A; Erwood A; Linder DF; Mendoza P; Morales B; Pradilla G; Nduom EK; Neill S; Olson JJ; Hoang KB
J Neurooncol; 2022 Mar; 157(1):187-195. PubMed ID: 35212929
[TBL] [Abstract][Full Text] [Related]
3. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
Tesileanu CMS; Dirven L; Wijnenga MMJ; Koekkoek JAF; Vincent AJPE; Dubbink HJ; Atmodimedjo PN; Kros JM; van Duinen SG; Smits M; Taphoorn MJB; French PJ; van den Bent MJ
Neuro Oncol; 2020 Apr; 22(4):515-523. PubMed ID: 31637414
[TBL] [Abstract][Full Text] [Related]
4. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
[TBL] [Abstract][Full Text] [Related]
6. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
[TBL] [Abstract][Full Text] [Related]
7. Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma.
Vizcaino MA; Palsgrove DN; Yuan M; Giannini C; Cabrera-Aldana EE; Pallavajjala A; Burger PC; Rodriguez FJ
Brain Pathol; 2019 Mar; 29(2):193-204. PubMed ID: 30222900
[TBL] [Abstract][Full Text] [Related]
8. Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
Hasselblatt M; Jaber M; Reuss D; Grauer O; Bibo A; Terwey S; Schick U; Ebel H; Niederstadt T; Stummer W; von Deimling A; Paulus W
J Neuropathol Exp Neurol; 2018 Jun; 77(6):422-425. PubMed ID: 29444314
[TBL] [Abstract][Full Text] [Related]
9. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
[TBL] [Abstract][Full Text] [Related]
10. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB
Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777
[TBL] [Abstract][Full Text] [Related]
11. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
12. Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes.
Zhang Y; Lucas CG; Young JS; Morshed RA; McCoy L; Oberheim Bush NA; Taylor JW; Daras M; Butowski NA; Villanueva-Meyer JE; Cha S; Wrensch M; Wiencke JK; Lee JC; Pekmezci M; Phillips JJ; Perry A; Bollen AW; Aghi MK; Theodosopoulos P; Chang EF; Hervey-Jumper SL; Berger MS; Clarke JL; Chang SM; Molinaro AM; Solomon DA
Neuro Oncol; 2022 Oct; 24(10):1749-1762. PubMed ID: 35395677
[TBL] [Abstract][Full Text] [Related]
13. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
[TBL] [Abstract][Full Text] [Related]
14. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.
Wong QH; Li KK; Wang WW; Malta TM; Noushmehr H; Grabovska Y; Jones C; Chan AK; Kwan JS; Huang QJ; Wong GC; Li WC; Liu XZ; Chen H; Chan DT; Mao Y; Zhang ZY; Shi ZF; Ng HK
Mod Pathol; 2021 Jul; 34(7):1245-1260. PubMed ID: 33692446
[TBL] [Abstract][Full Text] [Related]
15. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
Ohba S; Yamada Y; Murayama K; Sandika E; Sasaki H; Yamada S; Abe M; Hasegawa M; Hirose Y
World Neurosurg; 2019 Jun; 126():e1042-e1049. PubMed ID: 30878754
[TBL] [Abstract][Full Text] [Related]
16. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.
Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE
J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886
[TBL] [Abstract][Full Text] [Related]
17. Integrated molecular characterization of IDH-mutant glioblastomas.
Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163
[TBL] [Abstract][Full Text] [Related]
18. T2-FLAIR Mismatch: An Imaging Biomarker for Children's
van Maren EA; Dankbaar JW; Wesseling P; Plasschaert S; Muhlebner A; Hoving EW; Robe PA; Snijders TJ; Hoogendijk R; Kranendonk MEG; Lequin MH
AJNR Am J Neuroradiol; 2024 Jun; 45(6):747-752. PubMed ID: 38724203
[TBL] [Abstract][Full Text] [Related]
19. Predicting TERT promoter mutation status using
Yamashita K; Hatae R; Kikuchi K; Kuga D; Hata N; Yamamoto H; Obara M; Yoshimoto K; Ishigami K; Togao O
Neuroradiology; 2023 Aug; 65(8):1205-1213. PubMed ID: 37308686
[TBL] [Abstract][Full Text] [Related]
20. IDH mutations in older patients with diffuse astrocytic gliomas.
Andrews C; Prayson RA
Ann Diagn Pathol; 2020 Dec; 49():151653. PubMed ID: 33137656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]